Regeneron shares slide despite Q1 beat

Revenue roseate 19% year-over-year to $3.605 cardinal for the 4th ended March 31, portion adjusted net came successful astatine $9.47 per share, some topping Wall Street forecasts of $3.49 cardinal and $8.94 per stock respectively, according to LSEG information cited by Reuters.

Regeneron recorded $1.6 cardinal successful Sanofi collaboration gross during the quarter, reflecting astir 36% year-over-year growth, arsenic planetary nett income of its asthma therapy Dupixent jumped astir 33% year-over-year to $4.9 billion.

The company's oculus attraction therapy Eylea, marketed successful concern with Bayer, generated $1.7 cardinal successful planetary revenue, though that fig marked a 12% diminution from a twelvemonth ago.

The modular mentation of the attraction brought successful $869.3 million, a astir 40% year-over-year driblet amid competitory pressures. Its high-dose version, Eylea HD, offset immoderate of that weakness, contributing $800.9 cardinal connected astir 77% year-over-year maturation arsenic stronger uptake lifted income volumes.

Gross borderline connected nett merchandise income came successful astatine 76%, down from 81% successful the prior-year period, portion GAAP nett income per diluted stock fell astir 7% year-over-year to $6.75.

Regeneron near its 2026 outlook mostly unchanged but trimmed its guidance for GAAP gross borderline to a scope of 77% to 78%, from a anterior scope of 79% to 80%.